Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Beam Therapeutics Inc. Banner

Beam Therapeutics Inc.

BEAM Stock Analysis

Page title

Section title

About Beam Therapeutics Inc.

Biotechnology
Healthcare

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders...

Beam Therapeutics Inc. Key Metrics

Market Cap
$2B
52 Weeks Low
$16.95
52 Weeks High
$49.50
P/B
2.46x
P/E
-14.68x
P/S
5.96x

Upcoming Events

    BEAM Analyst Forecasts

    ‌
    ‌

    BEAM Financials

    BEAM Income Statement Key Metrics

    • Revenue(TTM)352.57 M
    • Gross Profit(TTM)328.72 M
    • EBITDA(TTM)-167.55 M
    • Net Income(TTM)-143.01 M
    • EPS Diluted(TTM)-1.8100000000000003

    Decode BEAM's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    BEAM earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of BEAM (0.947) is higher than the average of its peers (0.591).

    Net Profit Margin vs Peers

    Net profit margin ratio of BEAM (-0.351) is higher than the average of its peers (-4.133).

    BEAM Return on Equity

    See how efficiently BEAM generates profit for it's shareholders.

    -13.50%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of BEAM (-0.135) is higher than the average of its peers (-0.511).

    Return on Equity Growth

    BEAM's Return on Equity has grown significantly over the past 10 years, increasing by over 31.52%.

    BEAM Revenue Growth

    See how BEAM has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    BEAM's revenue has grown significantly over the past 10 years, increasing by over 0%.